Fennec (FENC) CMO Sayad Sargis Receives 168 Shares

What Happened
Sayad Pierre Sargis, Chief Medical Officer of Fennec Pharmaceuticals, had 168 shares reported as an award/acquisition on 2026-07-31. The reported acquisition price is $0.00 (code A — award/grant), producing a total reported value of $0. These were not an open‑market purchase or sale but a release of previously restricted shares.

Key Details

• Transaction date: 2026-07-31; Form filed: 2026-08-03. (Investors may check filing timeliness against SEC 2-business-day rules.)
• Transaction type/code: Award/Grant (A).
• Shares: 168 shares acquired at $0.00; total reported value $0.
• Shares owned after transaction: Not disclosed in the filing.
• Footnote: F1 — these 168 shares were released from restriction and originate from shares awarded on 2025-03-28.
• No indication in this filing of subsequent sales, tax withholding, or a 10b5-1 plan.

Context
This was a vesting/release of previously awarded restricted stock, not a market purchase or sale. Such releases reflect prior compensation arrangements and do not by themselves indicate an insider buying or selling to express a view of the stock. Retail investors should treat awards and restricted‑share releases as compensation events rather than direct signals of insider market sentiment.